

Brain Tumor End Points Workshop
January 20, 2006
Bethesda North Marriott Hotel and Conference Center
5701 Marinelli Road, Bethesda, MD

Presented by the U.S. Food and Drug Administration and the American Association for Cancer Research
Co-sponsored by the American Society of Clinical Oncology

Biomarker & Endpoint Research Priorities
4:00 – 5:00 p.m.

In this last session of the workshop, the panelists will consider what additional research may be required to move the most promising endpoints/biomarkers along to the next step.

Discussion Leaders

Jeffrey Abrams, MD

Chief, Clinical Investigations Branch,
Cancer Therapy and Evaluation Program,
Division of Cancer Treatment & Diagnosis,
National Cancer Institute, NIH
Rockville, MD 20852

Lalitha Shankar, MD, PhD

Medical Officer
Cancer Imaging Program
Division of Cancer Treatment & Diagnosis,
National Cancer Institute, NIH
Bethesda, MD 20892-7412

Tracy Lugo-Lively, PhD

Program Director
Diagnostics Evaluation Branch
Cancer Diagnosis Program
Division of Cancer Treatment & Diagnosis,
National Cancer Institute, NIH
Bethesda, MD 20892

Questions

- Which endpoints appear most promising and ready or nearly ready for clinical/regulatory application?
- What strategies are required to validate the most promising endpoints?
 - Are there ongoing or planned clinical trials which could incorporate these endpoints to facilitate validation?
- What are the most promising strategies to identify the next generation of promising endpoints/biomarkers for development?
 - What are the leading candidates for near-term development?
- How should the various promising imaging modalities be developed as biomarkers?